FY2024 Earnings Forecast for SPRY Issued By Leerink Partnrs

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will earn ($0.70) per share for the year, down from their prior forecast of ($0.60). The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.56) per share. Leerink Partnrs also issued estimates for ARS Pharmaceuticals' Q4 2024 earnings at ($0.27) EPS, FY2025 earnings at $0.70 EPS and FY2026 earnings at $0.05 EPS.

Several other brokerages have also commented on SPRY. Leerink Partners boosted their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an "outperform" rating in a research report on Friday, September 20th. Raymond James raised shares of ARS Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and boosted their price objective for the company from $18.00 to $22.00 in a research note on Tuesday, August 13th. William Blair upgraded ARS Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $24.00.

ARS Pharmaceuticals Trading Down 1.6 %

Shares of NASDAQ SPRY traded down $0.23 during midday trading on Monday, reaching $13.78. 1,056,668 shares of the company were exchanged, compared to its average volume of 812,128. The stock has a fifty day simple moving average of $14.67 and a 200 day simple moving average of $11.78. ARS Pharmaceuticals has a 1 year low of $4.64 and a 1 year high of $18.51. The stock has a market cap of $1.34 billion, a P/E ratio of -27.02 and a beta of 0.90.

Insider Transactions at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, major shareholder James E. Flynn sold 528,456 shares of ARS Pharmaceuticals stock in a transaction on Monday, November 11th. The shares were sold at an average price of $18.04, for a total transaction of $9,533,346.24. Following the sale, the insider now owns 5,274,735 shares in the company, valued at $95,156,219.40. The trade was a 9.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Brian Dorsey sold 50,000 shares of the business's stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $15.00, for a total transaction of $750,000.00. Following the completion of the sale, the chief operating officer now directly owns 6,024 shares in the company, valued at $90,360. This trade represents a 89.25 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,574,351 shares of company stock worth $24,012,378. 40.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. J.W. Cole Advisors Inc. raised its stake in shares of ARS Pharmaceuticals by 10.8% during the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company's stock worth $131,000 after buying an additional 1,500 shares during the last quarter. nVerses Capital LLC acquired a new stake in ARS Pharmaceuticals during the 3rd quarter worth $30,000. Creative Planning raised its position in shares of ARS Pharmaceuticals by 7.0% during the 3rd quarter. Creative Planning now owns 35,263 shares of the company's stock valued at $511,000 after acquiring an additional 2,307 shares during the last quarter. Levin Capital Strategies L.P. lifted its stake in shares of ARS Pharmaceuticals by 5.7% in the 1st quarter. Levin Capital Strategies L.P. now owns 55,250 shares of the company's stock valued at $565,000 after purchasing an additional 3,000 shares during the period. Finally, HighTower Advisors LLC boosted its position in shares of ARS Pharmaceuticals by 18.2% in the 3rd quarter. HighTower Advisors LLC now owns 28,310 shares of the company's stock worth $411,000 after purchasing an additional 4,369 shares during the last quarter. 68.16% of the stock is owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.